Drugs in a class of Type 2 diabetes medications known as DPP-4 inhibitors may not increase the short-term risk of pancreatic cancer, but the long-term risks are still unknown, according to a new study published in the journal Diabetes, Obesity and Metabolism. The study was conducted by researchers with the University of North Carolina (UNC) Gillings School of Global Public Health and the UNC School of medicine, and focused on pancreatic cancer risks with DPP-4 inhibitors such as Januvia and Janumet (sitagliptin), and Tradjenta (linagliptin). DPP-4 inhibitors were first marketed in the United States in 2006 and have since become ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.